![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1326556
¼¼°èÀÇ »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø, ±â¿øº°, Á¦Ç° ¼ºñ½ºº°, Áúº´ ÀûÀÀÁõº°, Áö¿ªº° ºÐ¼®(2023-2030³â)Global Biologics Contract Development Market Size Study & Forecast, By Source, by Product Service, by Disease Indication and Regional Analysis, 2023-2030 |
¼¼°è »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀåÀº 2022³â ¾à 60¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£ÀÎ 2023-2030³â 10.5% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
»ý¹°ÀǾàǰ À§Å¹°³¹ßÀº »ý¹°ÇÐÀû Á¦Á¦³ª Ä¡·áÁ¦ÀÇ °³¹ß ¹× Á¦Á¶ ¼ºñ½º¸¦ °³¹ß ¹× Á¦Á¶¼öʱâ°ü(CDMO) ¶Ç´Â ¿¬±¸°³¹ß¼öʱâ°ü(CRO)¿¡ À§Å¹ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ´Ü¹éÁú, Ç×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·áÁ¦ µî »ýü À¯·¡ÀÇ º¹ÀâÇÑ ºÐÀÚ¸¦ ¸»ÇÕ´Ï´Ù. »ý¹°ÇÐÀû »ý»ê¿¡ ÷´Ü ±â¼ú µµÀÔÀÌ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀåÀÇ Ã˸ÅÁ¦·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾àȸ»çÀÇ ÀǾàǰ °³¹ß ¹æ¹ý Áõ°¡, ½ÄǰÀǾ౹ÀÇ ÀǾàǰ ½ÂÀÎÀ² Áõ°¡, Ç¥Àû ¾à¸®¿ä¹ýÀÇ »ç¿ë Áõ°¡, °³ÀÎ ¸ÂÃãÇü ¾à¹°¿ä¹ý¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡ µîµµ ½ÃÀå ¼ºÀåÀÇ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½Å°æÁúȯ, ºÎÀΰúÁúȯ, ¾Ï, ¾È°úÁúȯ, ½ÉÇ÷°üÁúȯ µî ÁúȯÀÇ ±ÞÁõÀº ¼¼°è ½ÃÀå °³Ã´¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.2022³â ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é ¾ÏÀº ¼¼°è ÁÖ¿ä »ç¸Á¿øÀÎ Áß Çϳª·Î 2020³â 1,000¸¸ ¸í ÀÌ»óÀÌ »ç¸ÁÇß½À´Ï´Ù. Cancer TomorrowÀÇ ¿¹Ãø¿¡ µû¸£¸é 2020³â¿¡´Â ¾à 1,930¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ º¸°íµÉ °ÍÀ̸ç, ÀÌ ¼öÄ¡´Â 2040³â±îÁö 3,020¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ »óȲ¿¡¼ ÇコÄɾî CDMO´Â ȯÀÚ Ä¡·á¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ¿Ö³ÄÇÏ¸é ¸¹Àº ¹ÙÀÌ¿À Á¦¾à±â¾÷µéÀÌ Áúº´ Ä¡·á¸¦ À§ÇÑ ½Å¾àÀ̳ª µ¿±Þ ÃÖ°ÀÇ Á¦Ç°À» °³¹ßÇϰíÀÚ Çϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, »ý¹°ÇÐÀû Á¦Á¦ °³¹ßÀ» À§ÇÑ Ã·´Ü ±â¼ú äÅà Áõ°¡, ½ÅÈï±¹ÀÇ ÀÓ»ó½ÃÇè¿¡ À¯¸®ÇÑ È¯°æ, ÷´Ü »ý¹°ÇÐÀû Á¦Á¦ °³¹ßÀ» À§ÇÑ ÇöÁö ±â¾÷°úÀÇ Á¦ÈÞ, °è¾à ¹× ÇÕº´ Áõ°¡, ¹ÙÀÌ¿À Á¦¾à ºÎ¹®ÀÇ Á¦Á¶ À¯¿¬¼ºÀ» ³ôÀ̱â À§ÇÑ °³¹ß Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» À§ÇÑ ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª »ý¹°ÇÐÀû Á¦Á¦ Á¦Á¶ °øÁ¤ÀÇ ³ôÀº ºñ¿ë°ú ÀÌ·¯ÇÑ Á¦Ç°ÀÇ »ç¿ë¹ý¿¡ ´ëÇÑ ÀÌÇØ ºÎÁ·Àº »ý¹°Á¦Á¦ ¼öŹ °³¹ß »ê¾÷ÀÇ ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.
¼¼°è »ý¹°Á¦Á¦ ¼öŹ °³¹ß ½ÃÀåÀ» Á¶»çÇÏ´Â ÁÖ¿ä Áö¿ªÀ¸·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«°¡ ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â 2021³â ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü·«Àû Á¦ÈÞ ¹× Àμö, Àü¹® ½ÃÇè ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. CDO(Contract Development Organization)ÀÇ ¼ºÀåÀº ÁÖ·Î ÀÌ Áö¿ªÀÇ ÀÓ»ó½ÃÇè ¹× ¾Æ¿ô¼Ò½Ì Ȱµ¿ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ÀÌ Áö¿ªÀÇ ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â Áö¿ªÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ ¼¼°è ¿ä±¸¿¡ µû¶ó ÀÓ»ó½ÃÇè Æò°¡ ±âÁØÀ» ¾÷µ¥ÀÌÆ®Çϱâ À§ÇØ ´Ù¾çÇÑ ±ÔÁ¦ ±â°üÀÌ Á¶Á¤µÇ°í Àֱ⠶§¹®¿¡ »ý¸í °øÇÐ ±â¾÷µéÀº ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.
ÀÌ ¿¬±¸ÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû/¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.
¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚµéÀÌ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¹Ì½ÃÀû ½ÃÀå¿¡¼ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.
Global Biologics Contract Development Market is valued at approximately USD 6.08 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2023-2030. Biologics contract development refers to the outsourcing of development and manufacturing services for biologic drugs or therapies to contract development and manufacturing organizations (CDMOs) or contract research organizations (CROs). Biologics are complex molecules derived from living organisms, including proteins, antibodies, vaccines, and gene therapies. The rising adoption of advanced technology for biological production is acting as a catalyzing factor for market growth. Furthermore, increased drug development methods by pharmaceutical companies, increased drug approval rates by the Food and Drug Administration, increased use of targeted pharmacological therapies, and increased desire for personalized medication are some of the factors resulting in the increase in market growth.
In addition, the surging prevalence of diseases such as neurological illnesses, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders are contributing to the market development across the globe. According to World Health Organization in 2022, cancer is one of the main causes of death worldwide, accounting for over 10 million deaths in 2020. According to Cancer Tomorrow predictions in 2020, approximately 19.3 million cancer cases were reported in 2020, with this figure anticipated to climb to 30.2 million by 2040. In such circumstances, healthcare CDMOs play an important role in patient care because many biopharma companies aspire to develop novel medicines or first-in-class products for illness treatment. Furthermore, an increase in the adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries, an increase in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and an increase in the development of greater manufacturing flexibility in the biopharmaceutical sector is expected to provide lucrative opportunities for market growth over the forecasting period. However, the high cost of biologics production processes, as well as a lack of understanding about the usage of these products, limit the growth of the biologics contract development industry.
The key regions considered for the Global Biologics Contract Development Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to lead the market in 2021. Strategic collaborations and acquisitions, as well as growing demand for specialized testing services, are driving the market. The growth of contract development organizations (CDOs) can be attributed mostly to the region's increased clinical trial and outsourcing activity. Furthermore, the high prevalence of chronic diseases is substantial fostering the demand for clinical studies in this region. These factors drive market expansion. Asia Pacific is expected to be the fastest growing region during the forecast period, because of different regulatory organization adjustments to update clinical trial evaluation standards based on global needs, biotechnology businesses are investing in the Asia Pacific region.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: